Benzinga BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older. Importance Rank: 1 read more
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older. Importance Rank: 1 read more